Vanna Chiarion Sileni

Vanna Chiarion Sileni

UNVERIFIED PROFILE

Are you Vanna Chiarion Sileni?   Register this Author

Register author
Vanna Chiarion Sileni

Vanna Chiarion Sileni

Publications by authors named "Vanna Chiarion Sileni"

Are you Vanna Chiarion Sileni?   Register this Author

100Publications

10515Reads

11Profile Views

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2019 Oct 28;381(16):1535-1546. Epub 2019 Sep 28.

From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) - both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital, Siena (M.M.) - all in Italy; the University of Colorado Cancer Center, Aurora (R.G.); Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille Hôpital Timone, Marseille (J.-J.G.), and Université de Paris, INSERM Unité 976, Assistance Publique-Hôpitaux de Paris Dermatology and Centres d'Investigation Clinique, Saint Louis Hospital, Paris (C.L.) - both in France; the Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); the University of Michigan, Ann Arbor (C.D.L.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Universitäts Spital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB (M.S.), and the Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.H.), the Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney, Sydney, NSW (M.S.C., G.V.L.), and the Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and the Peter MacCallum Cancer Centre, Melbourne, VIC (G.M.) - all in Australia; General University Hospital Gregorio Marañon and Centro de Investigación Biomédica en Red de Oncología, Madrid (I.M.-R.); the Netherlands Cancer Institute, Amsterdam (J.H.); the Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Leuven, Leuven, Belgium (P.S.); University of California San Diego Health-La Jolla Moores Cancer Center, La Jolla (G.A.D.); the Department of Oncology, Odense University Hospital, Odense, Denmark (L.B.); Bristol-Myers Squibb, Princeton, NJ (J.I.R., A.B., A.M.); Dana-Farber Cancer Institute, Boston (F.S.H.); and the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910836DOI Listing
October 2019

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

N Engl J Med 2019 08 4;381(7):626-636. Epub 2019 Jun 4.

From Institut Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Aix-Marseille University, Marseille (J.J.G.), and Assistance Publique-Hôpitaux de Paris Dermatology and Clinical Investigation Center, Unité 976, Université de Paris, Hôpital Saint-Louis, Paris (C.L.) - all in France; Moscow City Oncology Hospital, Moscow (D. Stroyakovskiy), and the Petrov Research Institute of Oncology, St. Petersburg (E.L.) - both in Russia; Przychodnia Lekarska Komed, Konin (B.K.), the University of Medical Sciences, Poznań (A.M.), and the Maria Skłodowska-Curie Institute-Oncology Center, Warsaw (P.R.) - all in Poland; the University Hospital Schleswig-Holstein, Kiel (A.H.), the Department of Dermatology, University of Tübingen, Tübingen (C.G.), University Hospital Essen, Essen (D. Schadendorf), and the German Cancer Consortium, Heidelberg (D. Schadendorf) - all in Germany; the Veneto Institute of Oncology, Padua (V.C.S.), and Papa Giovanni XXIII Hospital, Bergamo (M.M.) - both in Italy; the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer (J.S.), and Sackler Medical School, Tel Aviv University, Tel Aviv (J.S.) - both in Israel; Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine (I.B.); Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens (H.G.); the Netherlands Cancer Institute, Amsterdam (J.B.A.G.H.); Mount Vernon Cancer Centre, Northwood, United Kingdom (P.D.N.); the University of California, Los Angeles, Los Angeles (A.R.); the University of Texas M.D. Anderson Cancer Center, Houston (M.A.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (K.T.F.); Novartis Pharma, Basel, Switzerland (P.B.); Novartis Pharmaceuticals, East Hanover, NJ (M.T., E.G., M.V.); and the Melanoma Institute Australia, the University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1904059DOI Listing
August 2019

Reply to E. Hindié and K.R. Hess.

J Clin Oncol 2019 May 2;37(15):1356-1358. Epub 2019 Apr 2.

Georgina V. Long, MD, PhD, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Reinhard Dummer, MD, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany; Mario Santinami, MD, Fondazione Istituto Nazionale Tumori, Milan, Italy; Victoria Atkinson, MD, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, and University of Queensland, Brisbane, QLD, Australia; Mario Mandalà, MD, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Vanna Chiarion-Sileni, MD, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy; James Larkin, MD, PhD, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Marta Nyakas, MD, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, MD, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; Andrew Haydon, MD, PhD, The Alfred Hospital, Melbourne, VIC, Australia; Caroline Robert, MD, PhD, Institute Gustave Roussy, Paris, France; Laurent Mortier, MD, PhD, Université de Lille, Institut National de la Santé et de la Recherche Médicale U 1189, Centre Hospitalier Universitaire Lille, Lille, France; Jacob Schachter, MD, PhD, Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv University, Tel Aviv, Israel; Thierry Lesimple, MD, MSc, Centre Eugène Marquis, Rennes, France; Ruth Plummer, MD, PhD, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Kohinoor Dasgupta, PhD, Novartis Healthcare, Hyderabad, India; Tomas Haas, PhD, Novartis AG, Basel, Switzerland; Mark Shilkrut, MD, PhD and Eduard Gasal, MD, Novartis Pharmaceuticals, East Hanover, NJ; Richard Kefford, MD, PhD, Melanoma Institute Australia, The University of Sydney, Macquarie University, and Westmead Hospital, Sydney, NSW, Australia; John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and Axel Hauschild, MD, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00004
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00004DOI Listing
May 2019

Cholecystectomy during esophagectomy is safe but unnecessary.

Acta Chir Belg 2019 Jan 8:1-7. Epub 2019 Jan 8.

e Department of upper GI surgery , Humanitas Research Hospital - Humanitas University , Rozzano (Milano) , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00015458.2018.1554364DOI Listing
January 2019

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma.

Scientifica (Cairo) 2018 30;2018:5036213. Epub 2018 Dec 30.

Unit of Dermatology, University of Padua, Via Gallucci 4, 35128 Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/5036213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332919PMC
December 2018

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

J Clin Oncol 2018 Oct 22:JCO1801219. Epub 2018 Oct 22.

Axel Hauschild, University Hospital Schleswig-Holstein, Kiel; Dirk Schadendorf, University Hospital Essen, Essen; German Cancer Consortium, Heidelberg, Germany; Reinhard Dummer, University Hospital Zürich Skin Cancer Center, Zürich; Tomas Haas, Novartis AG, Basel, Switzerland; Mario Santinami, Fondazione Istituto Nazionale Tumori, Milan; Mario Mandalà, Papa Giovanni XXIII Cancer Center Hospital, Bergamo; Vanna Chiarion-Sileni, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy; Victoria Atkinson, Princess Alexandra Hospital; Gallipoli Medical Research Foundation; University of Queensland, Brisbane, Queensland; Andrew Haydon, The Alfred Hospital, Melbourne, Victoria; Richard Kefford, Macquarie University; Westmead Hospital; Richard Kefford and Georgina V. Long, Melanoma Institute Australia; University of Sydney; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; James Larkin, Royal Marsden National Health Service Foundation Trust, London; Ruth Plummer, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Marta Nyakas, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux; Caroline Robert, Institute Gustave Roussy, Paris; Laurent Mortier, Université de Lille, Institut National de la Santé et de la Recherche Médicale U1189, Centre Hospitalier Universitaire de sa Region Lille, Lille; Thierry Lesimple, Centre Eugène Marquis, Rennes, France; Jacob Schachter, Sheba Medical Center, Tel Hashomer; Tel Aviv University, Tel Aviv, Israel; Kohinoor Dasgupta, Novartis Healthcare, Hyderabad, India; Mark Shilkrut and Eduard Gasal, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and John M. Kirkwood, UPMC Hillman Cancer Center; University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01219
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159PMC
October 2018

Time to diagnosis in esophageal cancer: a cohort study.

Acta Oncol 2018 Sep 30;57(9):1179-1184. Epub 2018 Mar 30.

e Department of Upper GI Surgery , Humanitas Research Hospital-Humanitas University , Rozzano , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2018.1457224DOI Listing
September 2018

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade.

J Transl Med 2018 04 11;16(1):94. Epub 2018 Apr 11.

Melanoma and Esophageal Cancer Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35128, Padua, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-018-1467-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896157PMC
April 2018

Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines.

Acta Derm Venereol 2018 Feb;98(2):218-224

Laboratory of Health Care Services and Health Promotion Evaluation, Unit of Hygiene and Public Health, Department of Cardiologic, Vascular, and Thoracic Sciences and Public Health, University of Padova, Via Loredan, 18, IT-35131 Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-2830DOI Listing
February 2018

Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev 2018 02 6;2:CD011123. Epub 2018 Feb 6.

Sarcoma Service, Fondazione IRCCS 'Istituto Nazionale Tumori', Via G. Venezian 1, Milano, Italy, 20133.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD011123.pub2
Publisher Site
http://dx.doi.org/10.1002/14651858.CD011123.pub2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491081PMC
February 2018

Esophageal Cancer Clinical Presentation: Trends in the Last 3 Decades in a Large Italian Series.

Ann Surg 2018 Jan;267(1):99-104

Esophageal and Digestive Tract Surgical Unit, Regional Centre for Oesophageal Disease, Veneto Institute of Oncology IOV IRCCS, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0000000000002048DOI Listing
January 2018

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

J Clin Oncol 2017 Dec 25;35(34):3807-3814. Epub 2017 Aug 25.

Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; Piotr Rutkowski, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy and Université Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.2289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791828PMC
December 2017

[Pembrolizumab for the treatment of melanoma: updates and perspectives.]

Recenti Prog Med 2017 Dec;108(12):528-531

Oncologia Medica 2, Ospedale San Martino, Genova.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1701/2829.28585DOI Listing
December 2017

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

N Engl J Med 2017 11 10;377(19):1813-1823. Epub 2017 Sep 10.

From the Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals (G.V.L.), and Macquarie University, Melanoma Institute Australia, University of Sydney, and Westmead Hospital (R.K.), Sydney, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane (V.A.), and Alfred Hospital, Melbourne, VIC (A. Haydon) - all in Australia; University Hospital Schleswig-Holstein, Kiel (A. Hauschild), and University Hospital Essen, Essen, and the German Cancer Consortium, Heidelberg (D.S.) - all in Germany; Fondazione Istituto Nazionale Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute, Padua (V.C.-S.) - all in Italy; Rikshospitalet-Radiumhospitalet, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux (C.D.), Institute Gustave Roussy, Paris (C.R.), Université de Lille, INSERM Unité 1189, Centre Hospitalier Régional Universitaire de Lille, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; Ella Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel (J.S.); Royal Marsden NHS Foundation Trust, London (J. Larkin), and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne (R.P.) - both in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (R.J., P.Z., B.M., J. Legos); University Hospital Zürich Skin Cancer Center, Zurich, Switzerland (R.D.); and the Melanoma Program, Hillman UPMC Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1708539
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1708539DOI Listing
November 2017

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

N Engl J Med 2017 11 10;377(19):1824-1835. Epub 2017 Sep 10.

From New York University Perlmutter Cancer Center, New York (J.W.); Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M. Mandala), Medical Oncology, National Cancer Institute, Milan (M.D.V.), Oncology Institute of Veneto Istituti di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M. Maio), Ospedale Policlinico San Martino, Genoa (P.Q.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; National and Kapodistrian University of Athens, Athens (H.J.G.); Hospital Clinic de Barcelona, Barcelona (A.M.A.), and General University Hospital Gregorio Marañón, Madrid (I.M.-R.) - both in Spain; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); Hospices Civils de Lyon, Pierre Bénite (S.D.), Aix-Marseille University, Hospital de la Timone, Marseille (J.-J.G.), Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), Toulouse (N.M.), Université Lille, INSERM Unité 1189, CHU Lille, Lille (L.M.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint Louis, Université Paris Diderot, Paris (C.L.) - all in France; Oncology Center Sf. Nectarie, Craiova, Romania (M. Schenker); Princess Margaret Cancer Centre, University of Toronto, Toronto (M.O.B.), and Cross Cancer Institute, Edmonton, AB (M. Smylie) - both in Canada; the Department of Oncology, University of Oxford, Oxford (M.R.M.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; Gallipoli Medical Research Foundation and University of Queensland, Queensland, VIC (V.A.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.) - all in Australia; University of Colorado, Denver (R.G.); Winship Cancer Institute, Emory University School of Medicine, Atlanta (R.R.K.); Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); University of Washington, Seattle (S.B.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Nagoya University Graduate School of Medicine, Nagoya (K.Y.), and the National Cancer Center Hospital, Tokyo (N.Y.) - both in Japan; Seoul National University Hospital, Seoul, South Korea (T.M.K.); and Bristol-Myers Squibb, Princeton, NJ (V.P, J.S., A.Q.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709030DOI Listing
November 2017

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.

J Chemother 2017 Aug 11;29(4):245-251. Epub 2017 Apr 11.

a Hospital Pharmacy , Veneto Institute of Oncology - IRCCS , Padua , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1120009X.2017.1311444DOI Listing
August 2017

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Eur J Cancer 2017 07 11;79:176-184. Epub 2017 May 11.

Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.04.007DOI Listing
July 2017

Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.

Cancer Treat Rev 2017 Mar 2;54:34-42. Epub 2017 Feb 2.

Meta-Analysis Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.01.006DOI Listing
March 2017

CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL.

Int J Technol Assess Health Care 2017 Jan 13;33(2):199-205. Epub 2017 Jul 13.

Hospital Pharmacy,Veneto Institute of

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S0266462317000332DOI Listing
January 2017

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

N Engl J Med 2016 11 7;375(19):1845-1855. Epub 2016 Oct 7.

From Gustave Roussy Cancer Campus Grand Paris, Villejuif (A.M.M.E., C.R.), Aix-Marseille University, Hôpital de La Timone, Marseille (J.-J.G.), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris (C.L.), University Lille, INSERM Unité-1189, Centre Hospitalier Universitaire (CHU) Lille, Service de Dermatologie, Lille (L.M.), and CHU Lyon, Lyon (L.T.) - all in France; the Oncology Institute of Veneto-Istituto di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Istituto Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Istituti Fisioterapici Ospitalieri, Rome (V.F.), University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), and the European Institute of Oncology, Milan (A.T.) - all in Italy; University of Zurich Hospital, Zurich, Switzerland (R.D.); Memorial Sloan Kettering Cancer Center, New York (J.D.W.); Aarhus University Hospital, Aarhus (H.S.), and Odense University Hospital, Odense (L.B.) - both in Denmark; the Angeles Clinic and Research Institute, Los Angeles (O.H.); Oncology Specialists, Park Ridge, IL (J.M.R.); Cross Cancer Institute, Edmonton, AB, Canada (M.S.); H. Lee Moffitt Cancer Center, Tampa, FL (J.S.W.); Broomfield Hospital, Chelmsford, United Kingdom (S.T.); Universitätsklinikum Schleswig-Holstein, Kiel (A.H.), and University Hospital Heidelberg, Heidelberg (J.C.H.) - both in Germany; Dana-Farber Cancer Institute, Boston (F.S.H.); Bristol-Myers Squibb, Princeton, NJ (C.T., V.P.); and the European Organization for Research and Treatment of Cancer, Brussels (G.S., S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648545PMC
November 2016

A germline predictive signature of response to platinum chemotherapy in esophageal cancer.

Transl Res 2016 May 22;171:29-37.e1. Epub 2015 Dec 22.

Immunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trsl.2015.12.011DOI Listing
May 2016

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

Future Oncol 2015 ;11(9):1355-62

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.55DOI Listing
February 2016

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med 2015 Jul 31;373(1):23-34. Epub 2015 May 31.

From the Department of Medical Oncology, Royal Marsden Hospital, London (J.L.), and South West Wales Cancer Institute, Singleton Hospital, Swansea (J.W.) - both in the United Kingdom; Melanoma Oncology Unit, Veneto Region Oncology Research Institute, Padua (V.C.-S.), Oncology of Melanoma Unit, European Institute of Oncology, Milan (P.F.F.), University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; Division of Medical Oncology, University of Colorado, Denver, Denver (R.G.); Aix-Marseille University, Hôpital de La Timone, Assitance Publique-Hôpitaux de Marseille, Marseille (J.J.G.), and Hôtel Dieu Place Alexis Ricordeau, Nantes (B.D.) - both in France; Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor (C.D.L.); Department of Dermatology, University of Essen, Essen, Germany (D.S.); University of Zürich Hospital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB, Canada (M. Smylie); Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland (P.R.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), and Westmead and Blacktown Hospitals (M.S.C.) and Melanoma Institute Australia (M.S.C., G.V.L.), University of Sydney, and the Mater Hospital (G.V.L.), Sydney, and Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC (G.A.M.) - all in Australia; Division of Medical Oncology, the Netherlands Cancer Institute, Amsterdam (J.B.H.); Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid (I.M.-R.); Ludwig Center, Memorial Sloan Kettering Cancer Center (M.K.C., M.A.P., J.D.W.) and Weill Cornell Medical College (M.K.C., M.A.P., J.D.W.) - both in New York; Huntsman Cancer Institute, University of Utah, Salt Lake City (K.G.); Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital, Yale University Sc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1504030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698905PMC
July 2015

A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments.

Melanoma Res 2015 Apr;25(2):164-8

aMelanoma and Esophageal Cancer Unit bInterventional Radiology Unit cSarcoma and Melanoma Unit, Veneto Region Oncology Research Institute (IOV-IRCCS) dDepartment of Statistics eDepartment of Ophthalmology fDepartment of Surgery, Oncology and Gastroenterology University of Padova, Padova gGB Bietti Foundation-IRCCS, Rome, Italy.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/melanomaresearch/2015/04000/A_r
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000129DOI Listing
April 2015

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

J Clin Oncol 2015 Apr 23;33(10):1191-6. Epub 2015 Feb 23.

Michele Maio, University Hospital of Siena, Siena; Vanna Chiarion-Sileni, Veneto Oncology Institute-Istituto Di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille; Luc Thomas, Lyon 1 University, Centre Hospitalier Lyon Sud, Pierre Bénite; Caroline Robert, Institute Gustave Roussy, Villejuif, France; Steinar Aamdal, Oslo University Hospital and Radium Hospital, Oslo, Norway; Igor Bondarenko, Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine; Claus Garbe, University Medical Center, Tübingen, Germany; Tai-Tsang Chen and Marina Tschaika, Bristol-Myers Squibb, Wallingford, CT; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.6018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795709PMC
April 2015

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib.

Radiol Oncol 2015 Mar 3;49(1):71-4. Epub 2015 Mar 3.

Melanoma Oncology Unit, Veneto Region Oncology Research Institute (IOV-IRCCS), Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/raon-2014-0035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362609PMC
March 2015

Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases.

Melanoma Res 2015 Feb;25(1):75-9

aMasonic Cancer Center, University of Minnesota, Minneapolis bDepartment of Medical Oncology, Mayo Clinic cMidwest Melanoma Partnership, Rochester, Minnesota dDivision of Hematology/Oncology, University of Illinois Cancer Center, Chicago, Illinois, USA eIstituto Oncologico, Veneto, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000133DOI Listing
February 2015

Neoadjuvant treatment with dabrafenib of unresectable localizations from occult melanoma.

Melanoma Res 2014 Aug;24(4):413-4

aMelanoma and Sarcoma Unit bMelanoma Cancer Unit cRadiology Unit dPathology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000083DOI Listing
August 2014

Melanoma Task Force (META) Project in Italy: methodology.

Dermatology 2013 29;226 Suppl 1:1-2. Epub 2013 May 29.

GfK Eurisko S.r.l., Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000348858DOI Listing
January 2014

Diagnostic services for melanoma in Italy.

Dermatology 2013 29;226 Suppl 1:3-6. Epub 2013 May 29.

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS IRST, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000348860DOI Listing
January 2014

Management of small and intermediate congenital nevi: a nationwide survey in Italy.

Dermatology 2013 29;226 Suppl 1:7-12. Epub 2013 May 29.

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS IRST, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000348861DOI Listing
January 2014

Impact of mole mapping in the Italian health system.

Dermatology 2013 29;226 Suppl 1:13-7. Epub 2013 May 29.

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS IRST, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000348863DOI Listing
January 2014

Surgical management of suspicious melanocytic lesions in Italy.

Dermatology 2013 29;226 Suppl 1:18-21. Epub 2013 May 29.

Dermatologic Clinic, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000348864DOI Listing
January 2014

Surgical treatment of melanoma: a survey of Italian hospitals.

Dermatology 2013 29;226 Suppl 1:28-31. Epub 2013 May 29.

Divisione Melanoma e Sarcomi Muscolo-Cutanei, Istituto Europeo di Oncologia, Milan, Italy. alessandro.testori @ ieo.it

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000348873DOI Listing
January 2014

Follow-up of melanoma: a survey of Italian hospitals.

Dermatology 2013 29;226 Suppl 1:32-8. Epub 2013 May 29.

Divisione Melanoma e Sarcomi Muscolo-Cutanei, Istituto Europeo di Oncologia, Milan, Italy. alessandro.testori @ ieo.it

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000348874DOI Listing
January 2014

Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma.

J Neurol Sci 2013 Dec 30;335(1-2):210-2. Epub 2013 Aug 30.

Melanoma Cancer Unit-SSD, Veneto Oncology Institute, 64 Gattamelata St, 35128 Padova, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2013.08.026DOI Listing
December 2013

Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: How does it affect the prognosis?

J Cancer Res Ther 2012 Oct-Dec;8(4):619-25

Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto, IOV - IRCCS, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0973-1482.106580DOI Listing
July 2013

Interferon alpha for the adjuvant treatment of cutaneous melanoma.

Cochrane Database Syst Rev 2013 Jun 18(6):CD008955. Epub 2013 Jun 18.

Meta-Analysis Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD008955.pub2DOI Listing
June 2013

Melanoma m (zero): diagnosis and therapy.

ISRN Dermatol 2013 11;2013:616170. Epub 2013 Apr 11.

Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV IRCCS, 35128 Padua, Italy.

View Article

Download full-text PDF

Source
https://www.hindawi.com/archive/2013/616170/
Publisher Site
http://dx.doi.org/10.1155/2013/616170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649440PMC
May 2013

The cost of unresectable stage III or stage IV melanoma in Italy.

J Exp Clin Cancer Res 2012 Nov 1;31:91. Epub 2012 Nov 1.

Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Strada delle Scotte, 53100, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-9966-31-91DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542007PMC
November 2012

A case of squamous cell carcinoma of the scalp after several synthetic hair grafts.

Aesthetic Plast Surg 2012 Jun 24;36(3):649-52. Epub 2012 Feb 24.

Clinic of Pediatric Plastic Surgery, Padua General Hospital, and Clinic of Plastic and Reconstructive Surgery, University of Padua, Padua, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00266-012-9875-4DOI Listing
June 2012

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

Cancer Immunol Immunother 2012 Jan 11;61(1):41-8. Epub 2011 Aug 11.

Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Istituto Toscano Tumori, Strada delle Scotte, 53100 Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-011-1089-0DOI Listing
January 2012

Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation.

Mutat Res 2009 Dec 25;671(1-2):26-32. Epub 2009 Aug 25.

Section of Oncology, Department of Oncology and Surgical Sciences, University of Padova, via Gattamelata, 64, I-35128 Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mrfmmm.2009.08.007DOI Listing
December 2009

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

J Immunol 2009 May;182(10):6562-8

Department of Oncology and Surgical Sciences, Oncology Section, University of Padova, Padova, Italy;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.0803831DOI Listing
May 2009

Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution.

Arch Surg 2009 Mar;144(3):247-54; discussion 254

Department of Gastrointestinal and Surgical Sciences, Clinica Chirurgica III, University of Padova School of Medicine, Via Giustiniani 2, 35128 Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archsurg.2008.574DOI Listing
March 2009

Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients.

Ann Surg Oncol 2009 Jan 6;16(1):191-9. Epub 2008 Nov 6.

Department of Oncological and Surgical Sciences, Istituto di Clinica Chirurgica Generale II, Policlinico Universitario, 6 degrees Piano Via Giustiniani 2, 33128, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-008-0204-8DOI Listing
January 2009